Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antibiotic Selection00:57

Antibiotic Selection

55.6K
Overview
55.6K
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

214
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
214
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

355
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
355
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

329
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
329

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Report of Dieback Caused by <i>Phytophthora ramorum</i> on Golden Chinquapin, <i>Chrysolepis chrysophylla,</i> in California.

Plant disease·2022
Same author

Cross-predicting the dynamics of an optically injected single-mode semiconductor laser using reservoir computing.

Chaos (Woodbury, N.Y.)·2019
Same author

First Report of Phytophthora ramorum Causing a Leafspot on Loropetalum chinense, Chinese Fringe Flower in California.

Plant disease·2019
Same author

First Report of Leaf Spot Caused by Phytophthora taxon Pgchlamydo on Evergreen Nursery Stock in California.

Plant disease·2019
Same author

Consistency properties of chaotic systems driven by time-delayed feedback.

Physical review. E·2018
Same author

Role of dynamical injection locking and characteristic pulse events for low frequency fluctuations in semiconductor lasers.

Chaos (Woodbury, N.Y.)·2017
Same journal

Nasal swab-guided deescalation of empirical linezolid in respiratory infections at a secondary-level hospital: quantification of quality gaps and antimicrobial stewardship opportunities.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

[Infectious complications following intravesical bacillus Calmette-Guérin therapy: a case series].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Associations between high-risk human papillomavirus genotypes: evidence of HPV16 predominance as a monoinfection and its no stronger link with high-grade lesions.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

Pediatric septic arthritis caused by <i>Staphylococcus argenteus</i>.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
Same journal

[Colonisation or early invasion? Disseminated aspergillosis after bronchial isolation of <i>Aspergillus fumigatus</i> in a heart transplant recipient].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2026
See all related articles

Related Experiment Video

Updated: Sep 25, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K

Cefiderocol.

M C Soriano1, J Montufar, A Blandino-Ortiz

  • 1María Cruz Soriano, Servicio Medicina Intensiva Hospital Universitario Ramón y Cajal, Madrid, Spain. cruzsorianocuesta@yahoo.es.

Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia
|April 30, 2022
PubMed
Summary
This summary is machine-generated.

Cefiderocol shows strong in vitro activity against resistant Gram-negative bacteria. Further real-world studies are needed to confirm its clinical efficacy and safety in treating pneumonia.

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.9K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K

Related Experiment Videos

Last Updated: Sep 25, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.9K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.1K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Microbiology

Background:

  • Cefiderocol is a novel siderophore cephalosporin.
  • It exhibits potent in vitro activity against challenging Gram-negative pathogens, including carbapenemase-producing Enterobacterales and difficult-to-treat non-fermenting Gram-negative bacteria.
  • As a beta-lactam antibiotic, its optimal use involves extended infusion and dose adjustments for renal impairment.

Purpose of the Study:

  • To evaluate the efficacy and safety of cefiderocol.
  • To assess its role in treating infections caused by multidrug-resistant Gram-negative bacteria.
  • To investigate its utility in hospital-acquired and ventilator-associated pneumonia.

Main Methods:

  • Clinical trials were conducted to validate cefiderocol's efficacy.
  • One trial specifically focused on treating hospital-acquired pneumonia and ventilator-associated pneumonia.
  • Another trial targeted infections caused by difficult-to-treat Gram-negative pathogens.

Main Results:

  • Cefiderocol demonstrated clinical and microbiological success in a trial targeting difficult-to-treat Gram-negative infections.
  • However, an observed increase in mortality in the cefiderocol arm necessitates further investigation.
  • Efficacy in real-world clinical practice requires additional demonstration.

Conclusions:

  • Cefiderocol is a promising option for treating Gram-negative bacilli carbapenem-resistant pneumonia.
  • Its effectiveness is optimized with extended perfusion, requiring dose adjustments in renal dysfunction.
  • Further real-world data is crucial to fully establish its clinical utility and safety profile.